<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Prescribing Advice for GPs &#187; Prescribing Formulary</title>
	<atom:link href="http://www.prescriber.org.uk/category/prescribing-formulary/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.prescriber.org.uk</link>
	<description>An NHS Prescribing Advisers&#039; Blog</description>
	<lastBuildDate>Wed, 08 Feb 2012 10:07:43 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Type 2 Diabetes - Update</title>
		<link>http://www.prescriber.org.uk/2007/10/type-2-diabetes-update/</link>
		<comments>http://www.prescriber.org.uk/2007/10/type-2-diabetes-update/#comments</comments>
		<pubDate>Tue, 02 Oct 2007 09:37:41 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/2007/10/02/type-2-diabetes-update/</guid>
		<description><![CDATA[Following the recent cardiovascular and fracture risk safety concerns associated with the glitazones and the introduction of a new class of hypoglycaemic, it seemed timely to review the Formulary Advice for type 2 diabetes. Blood pressure remains more important than blood glucose because tight blood pressure control was found to contribute to reductions in deaths [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2007/10/type-2-diabetes-update/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Statins Update</title>
		<link>http://www.prescriber.org.uk/2006/07/statins-update/</link>
		<comments>http://www.prescriber.org.uk/2006/07/statins-update/#comments</comments>
		<pubDate>Thu, 27 Jul 2006 09:54:15 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=202</guid>
		<description><![CDATA[Earlier this year the Summaries of Product Characteristics (SPC) for Atorvastatin (Lipitor&#174;) and Ezetimibe/Simvastatin (Inegy&#174;) were updated. These new documents list details of the expected reductions in total cholesterol from untreated baseline results. A previous article has suggested a stepped approach to lipid management however the information in the updated SPCs has changed this advice. [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2006/07/statins-update/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>Prevention of Fractures</title>
		<link>http://www.prescriber.org.uk/2006/07/prevention-of-fractures/</link>
		<comments>http://www.prescriber.org.uk/2006/07/prevention-of-fractures/#comments</comments>
		<pubDate>Wed, 19 Jul 2006 09:08:08 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=199</guid>
		<description><![CDATA[The National Institute of health and Clinical Excellence (NICE) published a technology appraisal on the secondary prevention of osteoporotic fractures in postmenopausal women in January 2005. NICE are also working on a similar appraisal aimed at primary prevention but until this is published it will be difficult to assess who to treat as primary prevention [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2006/07/prevention-of-fractures/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Seasonal Allergic Rhinitis</title>
		<link>http://www.prescriber.org.uk/2006/04/seasonal-allergic-rhinitis/</link>
		<comments>http://www.prescriber.org.uk/2006/04/seasonal-allergic-rhinitis/#comments</comments>
		<pubDate>Wed, 26 Apr 2006 15:09:59 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=172</guid>
		<description><![CDATA[Seasonal Allergic Rhinitis or Hayfever is a common condition that may affect up to 10% of the population between May and August. Treatment is based upon use of oral antihistamines and nasal corticosteroids. Prodigy categorises symptoms as follows: Mild intermittent Mild persistent or moderate-severe intermittent Moderate-severe persistent Treatment selection can be based upon the severity [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2006/04/seasonal-allergic-rhinitis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Proton Pump Inhibitors - Update</title>
		<link>http://www.prescriber.org.uk/2006/03/proton-pump-inhibitors-update/</link>
		<comments>http://www.prescriber.org.uk/2006/03/proton-pump-inhibitors-update/#comments</comments>
		<pubDate>Mon, 20 Mar 2006 21:32:05 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=151</guid>
		<description><![CDATA[The patent for the proton pump inhibitor (PPI) lansoprazole expired recently and several generic version are now available. In response to this the Drug Tariff has been updated to reflect a lower price for this drug. It has been added to Category M of the tariff and this has dramatically reduced the price. 28 capsules [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2006/03/proton-pump-inhibitors-update/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Proton Pump Inhibitors</title>
		<link>http://www.prescriber.org.uk/2005/12/proton-pump-inhibitors/</link>
		<comments>http://www.prescriber.org.uk/2005/12/proton-pump-inhibitors/#comments</comments>
		<pubDate>Sat, 17 Dec 2005 14:06:07 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=100</guid>
		<description><![CDATA[Proton Pump Inhibitors (PPI) are very common drugs that are used to treat gastrointestinal conditions associated with excess stomach acid production. Currently there are five PPIs available, omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole. A meta-analysis1 of 19 studies that directly compared PPIs with each another has assessed if there are any differences between these PPIs [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2005/12/proton-pump-inhibitors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Type II Diabetes</title>
		<link>http://www.prescriber.org.uk/2005/09/type-ii-diabetes/</link>
		<comments>http://www.prescriber.org.uk/2005/09/type-ii-diabetes/#comments</comments>
		<pubDate>Thu, 01 Sep 2005 10:18:49 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=35</guid>
		<description><![CDATA[Diabetes is a relatively common and very serious disease. The treatment of diabetes tends to focus upon the diagnostic measures for the disease, those of blood sugar assessment. Despite this the United Kingdom Prospective Diabetes Study1 (UKPDS) has shown the tight blood sugar control should be a secondary target to tight blood pressure control. Tight [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2005/09/type-ii-diabetes/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>Non-steroidal Anti-inflammatories (NSAIDs)</title>
		<link>http://www.prescriber.org.uk/2005/08/non-steroidal-anti-inflammatories-nsaids/</link>
		<comments>http://www.prescriber.org.uk/2005/08/non-steroidal-anti-inflammatories-nsaids/#comments</comments>
		<pubDate>Wed, 31 Aug 2005 07:22:24 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=34</guid>
		<description><![CDATA[The MHRA advice regarding the safety of NSAIDs has already been summarised on this site. The following recommendations apply in relation to the safe prescribing of NSAIDs: Review the patient for the overall risks involved with NSAID treatment - this should include an assessment of gastro-intestinal risk, cardio-vascular risk, renal risk as well as pre-treatment [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2005/08/non-steroidal-anti-inflammatories-nsaids/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Analgesia</title>
		<link>http://www.prescriber.org.uk/2005/08/analgesia/</link>
		<comments>http://www.prescriber.org.uk/2005/08/analgesia/#comments</comments>
		<pubDate>Wed, 31 Aug 2005 07:22:07 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=33</guid>
		<description><![CDATA[The safety of NSAIDs is under constant review at the moment following the concerns raised by the withdrawal of some of the newer COX-II Selective NSAIDs. The MHRA review has already been reported on this site. All interventions made by the NHS, including prescribing drugs, involves an assessment of the risks of the intervention and [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2005/08/analgesia/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hypertension</title>
		<link>http://www.prescriber.org.uk/2005/08/hypertension/</link>
		<comments>http://www.prescriber.org.uk/2005/08/hypertension/#comments</comments>
		<pubDate>Tue, 30 Aug 2005 14:48:19 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=32</guid>
		<description><![CDATA[NICE published a Clinical Guideline for Hypertension in August 2004. This guideline was based on the evidence available at the time and was probably dramatically influenced by the ALLHAT Study1. This Study was conducted in about 42,000 patients and compared active treatments as follows: Thiazide Diuretic (Chlorthalidone) ACE Inhibitor (Lisinopril) Calcium Channel Blocker (Amlodipine) Alpha [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2005/08/hypertension/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Statins</title>
		<link>http://www.prescriber.org.uk/2005/08/statins/</link>
		<comments>http://www.prescriber.org.uk/2005/08/statins/#comments</comments>
		<pubDate>Wed, 24 Aug 2005 11:13:27 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=28</guid>
		<description><![CDATA[A recommendation has already been made regarding changing statin therapy following the implementation of the new Pharmacy Contract. There is much discussion at present about the likely changes to the GMS contract and the targets contained within it regarding cholesterol. Broadly speaking there are two sides to the argument, the "fire and forget" approach and [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2005/08/statins/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Antiplatelets</title>
		<link>http://www.prescriber.org.uk/2005/08/antiplatelets/</link>
		<comments>http://www.prescriber.org.uk/2005/08/antiplatelets/#comments</comments>
		<pubDate>Wed, 24 Aug 2005 10:34:39 +0000</pubDate>
		<dc:creator>Matthew Robinson</dc:creator>
				<category><![CDATA[Prescribing Formulary]]></category>

		<guid isPermaLink="false">http://www.prescriber.org.uk/?p=27</guid>
		<description><![CDATA[Antiplatelets should be prescribed to reduce the risk of a cardiovascular event. This risk reduction can be classified as primary or secondary prevention depending on whether the first or subsequent event is being prevented. The evidence for the most appropriate intervention differs between these two groups. Secondary Prevention is the reduction of risk of a [...]]]></description>
		<wfw:commentRss>http://www.prescriber.org.uk/2005/08/antiplatelets/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>

